Olutasidenib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Olutasidenib" in English language version.

refsWebsite

Global rank English rank

3nih.gov

4^th place

3fda.gov

447^th place

338^th place

2doi.org

2^nd place

2semanticscholar.org

11^th place

8^th place

1rigel.com

low place

1prnewswire.com

406^th place

258^th place

1figshare.com

5,893^rd place

3,320^th place

1handle.net

102^nd place

76^th place

doi.org

Kang C (March 2023). "Olutasidenib: First Approval". Drugs. 83 (4): 341–346. doi:10.1007/s40265-023-01844-1. PMID 36848032. S2CID 257218495.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. (January 2023). "Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial". The Lancet. Haematology. 10 (1): e46–e58. doi:10.1016/s2352-3026(22)00292-7. PMID 36370742. S2CID 253471380.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

accessdata.fda.gov

Theoret MR (December 2022). "REZLIDHIA (olutasidenib) capsules" (PDF). Approval Letter. U.S. Food and Drug Administration. This article incorporates text from this source, which is in the public domain.

fda.gov

"FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation". U.S. Food and Drug Administration (FDA). 1 December 2022. Retrieved 20 December 2022.

figshare.com

Kang C (March 2023). "Olutasidenib: First Approval". Drugs. 83 (4): 341–346. doi:10.1007/s40265-023-01844-1. PMID 36848032. S2CID 257218495.

handle.net

hdl.handle.net

World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kang C (March 2023). "Olutasidenib: First Approval". Drugs. 83 (4): 341–346. doi:10.1007/s40265-023-01844-1. PMID 36848032. S2CID 257218495.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. (January 2023). "Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial". The Lancet. Haematology. 10 (1): e46–e58. doi:10.1016/s2352-3026(22)00292-7. PMID 36370742. S2CID 253471380.

dailymed.nlm.nih.gov

"Rezlidhia- olutasidenib capsule". DailyMed. U.S. National Library of Medicine. 13 December 2022. Retrieved 21 January 2023.

prnewswire.com

"Rigel Announces U.S. FDA Approval of Rezlidhia (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation" (Press release). Rigel Pharmaceuticals. 1 December 2022. Retrieved 2 December 2022 – via PR Newswire.

rigel.com

"Rigel Announces U.S. FDA Approval of Rezlidhia (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation". Rigel Pharmaceuticals, Inc. (Press release). 1 December 2022. Retrieved 2 December 2022.

semanticscholar.org

api.semanticscholar.org

Kang C (March 2023). "Olutasidenib: First Approval". Drugs. 83 (4): 341–346. doi:10.1007/s40265-023-01844-1. PMID 36848032. S2CID 257218495.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. (January 2023). "Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial". The Lancet. Haematology. 10 (1): e46–e58. doi:10.1016/s2352-3026(22)00292-7. PMID 36370742. S2CID 253471380.